Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet Respir Med · 2022 · PMC9451499 · PMID 36087611

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Third, the time-to-event Cox regression analysis stratified for site did not reach statistical significance, whereas all other analyses showed a significant reduction in all-cause mortality at 28 and 60 days with vilobelimab compared with placebo.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.